Arvee Laboratories (India) Limited (ARVEE) - Total Liabilities
Based on the latest financial reports, Arvee Laboratories (India) Limited (ARVEE) has total liabilities worth Rs91.40 Million INR (≈ $988.48K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arvee Laboratories (India) Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Arvee Laboratories (India) Limited's total liabilities have evolved over time, based on quarterly financial data. See ARVEE net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Arvee Laboratories (India) Limited Competitors by Total Liabilities
The table below lists competitors of Arvee Laboratories (India) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sensei Biotherapeutics Inc
NASDAQ:SNSE
|
USA | $14.19 Million |
|
Maisons du Monde SAS
PA:MDM
|
France | €1.06 Billion |
|
Haily Group Bhd
KLSE:0237
|
Malaysia | RM131.88 Million |
|
Law Debenture Corp
LSE:LWDB
|
UK | GBX191.35 Million |
|
SKY E&M Co. Ltd
KQ:131100
|
Korea | ₩25.99 Billion |
|
Orbital Corporation Ltd
AU:OEC
|
Australia | AU$8.85 Million |
|
Caldwell Partners International Inc
TO:CWL
|
Canada | CA$36.43 Million |
|
BMG Resources Ltd
AU:BMG
|
Australia | AU$76.70K |
Liability Composition Analysis (2013–2025)
This chart breaks down Arvee Laboratories (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARVEE stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arvee Laboratories (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arvee Laboratories (India) Limited (2013–2025)
The table below shows the annual total liabilities of Arvee Laboratories (India) Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs68.97 Million ≈ $745.87K |
-24.08% |
| 2024-03-31 | Rs90.85 Million ≈ $982.46K |
-14.48% |
| 2023-03-31 | Rs106.23 Million ≈ $1.15 Million |
-27.94% |
| 2022-03-31 | Rs147.43 Million ≈ $1.59 Million |
-24.81% |
| 2021-03-31 | Rs196.08 Million ≈ $2.12 Million |
+31.28% |
| 2020-03-31 | Rs149.36 Million ≈ $1.62 Million |
-27.80% |
| 2019-03-31 | Rs206.88 Million ≈ $2.24 Million |
-30.85% |
| 2018-03-31 | Rs299.18 Million ≈ $3.24 Million |
-4.96% |
| 2017-03-31 | Rs314.81 Million ≈ $3.40 Million |
-3.34% |
| 2016-03-31 | Rs325.69 Million ≈ $3.52 Million |
+32.32% |
| 2015-03-31 | Rs246.14 Million ≈ $2.66 Million |
+71.40% |
| 2014-03-31 | Rs143.60 Million ≈ $1.55 Million |
+62.92% |
| 2013-03-31 | Rs88.14 Million ≈ $953.24K |
-- |
About Arvee Laboratories (India) Limited
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroi… Read more